Revenue (TTM) Chart

Historical Revenue (TTM) Data

View and export this data back to 2013. Start Trial.
Date Value
September 30, 2026 4.75M
June 30, 2026 6.491M
March 31, 2026 6.316M
December 31, 2025 6.646M
September 30, 2025 7.137M
June 30, 2025 8.47M
March 31, 2025 13.34M
December 31, 2024 13.63M
September 30, 2024 13.45M
June 30, 2024 12.32M
March 31, 2024 6.478M
December 31, 2023 63.53M
September 30, 2023 106.21M
June 30, 2023 119.25M
March 31, 2023 136.87M
December 31, 2022 96.30M
September 30, 2022 69.01M
June 30, 2022 68.26M
March 31, 2022 63.12M
December 31, 2021 55.85M
September 30, 2021 54.68M
June 30, 2021 48.01M
March 31, 2021 40.06M
December 31, 2020 31.43M
September 30, 2020 18.34M
Date Value
June 30, 2020 13.21M
March 31, 2020 10.56M
December 31, 2019 10.68M
September 30, 2019 9.539M
June 30, 2019 8.136M
March 31, 2019 6.346M
December 31, 2018 4.74M
September 30, 2018 4.106M
June 30, 2018 4.106M
March 31, 2018 4.105M
December 31, 2017 4.106M
September 30, 2017 4.106M
June 30, 2017 4.106M
March 31, 2017 4.107M
December 31, 2016 4.402M
September 30, 2016 4.451M
June 30, 2016 4.451M
March 31, 2016 3.753M
December 31, 2015 2.431M
September 30, 2015 1.355M
June 30, 2015 0.329M
March 31, 2015 0.00
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 0.209M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (TTM) Range, Past 5 Years

View Revenue (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (TTM) Benchmarks

View Revenue (TTM) Benchmarks
Start Trial
AVITA Medical, Inc. 84.68M
Agenus, Inc. 133.95M
Amgen, Inc. 38.98B
Anika Therapeutics, Inc. 123.43M
BioCryst Pharmaceuticals, Inc. 961.51M